Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Int J Mol Sci. 2018 Apr 23;19(4):1260. doi: 10.3390/ijms19041260.
The prevalence of obesity and atherosclerosis has substantially increased worldwide over the past several decades. Peroxisome proliferator-activated receptors (PPARs), as fatty acids sensors, have been therapeutic targets in several human lipid metabolic diseases, such as obesity, atherosclerosis, diabetes, hyperlipidaemia, and non-alcoholic fatty liver disease. Constitutive androstane receptor (CAR) and liver X receptors (LXRs) were also reported as potential therapeutic targets for the treatment of obesity and atherosclerosis, respectively. Further clarification of the internal relationships between these three lipid metabolic nuclear receptors is necessary to enable drug discovery. In this review, we mainly summarized the cross-talk of PPARs-CAR in obesity and PPARs-LXRs in atherosclerosis.
在过去的几十年中，肥胖症和动脉粥样硬化在全球范围内的患病率显著增加。过氧化物酶体增殖物激活受体 (PPAR) 作为脂肪酸传感器，已成为几种人类脂质代谢疾病（如肥胖症、动脉粥样硬化、糖尿病、高脂血症和非酒精性脂肪肝疾病）的治疗靶点。组成型雄烷受体 (CAR) 和肝 X 受体 (LXR) 也分别被报道为肥胖症和动脉粥样硬化治疗的潜在治疗靶点。为了促进药物研发，有必要进一步阐明这三种脂质代谢核受体之间的内在关系。在这篇综述中，我们主要总结了肥胖症中 PPAR-CAR 的相互作用和动脉粥样硬化中 PPAR-LXR 的相互作用。
